Plant Name: Erycibe schmidtii
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.305E-11 | 1.034E-07 | CA1, CA12, CA13, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.604E-09 | 5.822E-06 | CA1, CA12, CA13, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 4.585E-09 | 1.248E-05 | CA1, CA12, CA13, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 4.374E-08 | 6.350E-05 | FABP2, FABP3, FABP4, FABP5 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 4.836E-08 | 6.581E-05 | AKR1B1, AKR1B10, APP, CYP1A2, CYP2C19, CYP2D6, PPARD |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 5.440E-08 | 6.968E-05 | CYP1A2, CYP2C19, CYP2D6 |
| MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 4.606E-07 | 2.896E-04 | AKR1B1, AKR1B10, ALDH1A1, XDH |
| BP | GO:0008152; metabolic process | GO:0017144; drug metabolic process | 5.673E-07 | 3.251E-04 | AKR1B1, AKR1B10, ALDH1A1, CYP1A2, CYP2C19, CYP2D6, DRD1, TLR2 |
| BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 1.613E-06 | 8.363E-04 | CASP1, HIF1A, LMNA, PPARA, PPARD, TLR2 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.086E-06 | 1.461E-03 | ALOX15, CYP1A2, CYP2C19, CYP2D6, XDH |
| BP | GO:0032501; multicellular organismal process | GO:0014005; microglia development | 6.074E-06 | 2.467E-03 | APP, TLR2 |
| BP | GO:0050896; response to stimulus | GO:0009719; response to endogenous stimulus | 6.498E-06 | 2.573E-03 | AKR1B1, APP, CA9, CASP7, CYP1A2, DRD1, FABP3, PPARA, TLR2 |
| BP | GO:0032501; multicellular organismal process | GO:0032640; tumor necrosis factor production | 1.214E-05 | 4.004E-03 | APP, TLR2 |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 1.316E-05 | 4.214E-03 | AKR1B1, AKR1B10, ALDH1A1, ALOX15, APP, CA1, CA13, CA7, CASP1, CASP7, FABP2, FABP3, FABP4, FABP5, GFER, HIF1A, LMNA, XDH |
| BP | GO:0065007; biological regulation | GO:0065008; regulation of biological quality | 1.444E-05 | 4.497E-03 | AKR1B1, ALDH1A1, ALOX15, APP, CA12, CA7, CASP1, DRD1, FABP3, FABP4, HIF1A, PPARA, PPARD, TLR2, XDH |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 2.256E-11 | 1.692E-09 | CA12; CA1; CA7; CA9; CA13 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 4.791E-10 | 1.797E-08 | FABP2; FABP3; FABP4; FABP5; PPARA; PPARD |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.720E-05 | 2.828E-04 | APP; CYP2D6; ALOX15; CYP2C19 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 8.763E-06 | 2.191E-04 | CYP1A2; ALOX15; CYP2C19 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 6.140E-05 | 7.675E-04 | CASP7; CASP1; TLR2 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.158E-04 | 2.024E-03 | AKR1B10; CYP1A2; ALOX15; ALDH1A1; AKR1B1; CYP2C19; HSD17B10; XDH |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.210E-04 | 1.297E-03 | CYP2D6; CYP1A2; CYP2C19 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.634E-03 | 1.022E-02 | APP; CASP7; HSD17B10 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 1.156E-03 | 7.883E-03 | AKR1B10; AKR1B1 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 8.025E-04 | 6.687E-03 | AKR1B10; AKR1B1 |
| hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 3.078E-03 | 1.776E-02 | AKR1B10; AKR1B1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 3.393E-03 | 1.818E-02 | ALOX15; CYP2C19 |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 9.134E-04 | 6.851E-03 | AKR1B10; AKR1B1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 3.723E-03 | 1.861E-02 | CYP1A2; ALDH1A1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 4.671E-03 | 2.172E-02 | CYP2D6; CYP1A2 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 4.924E-03 | 2.172E-02 | CASP7; CASP1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 5.857E-03 | 2.441E-02 | CYP1A2; CYP2C19 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.885E-05 | 2.828E-04 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CASP1; AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TLR2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD1 |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | DRD1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; XDH |
| C00-D49: Neoplasms | Glioma | C71 | APP |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; AKR1B1 |
| NA: NA | Geographic retinal atrophy | NA | APP |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD1 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | APP |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | DRD1 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | APP |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| NA: NA | Dyslipidemia | NA | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARD; PPARD |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD1 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | DRD1 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | DRD1 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | DRD1 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PPARD; DRD1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD |
| C00-D49: Neoplasms | Prostate cancer | C61 | TLR2 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD1 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | DRD1 |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; CA9; TLR2 |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2 |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; CA1; CA9; TLR2; APP |